The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer
KMT2D is a critical regulator of chromatin accessibility and transcriptional landscapes in castration-resistant prostate cancer that drives both AR-dependent and AR-independent subtypes, highlighting KMT2D as a potential therapeutic target.
Authors
- Yangzhenyu Gao (ORCID: https://orcid.org/0009-0009-5267-0122)
- Amaia Arruabarrena-Aristorena (ORCID: https://orcid.org/0000-0002-1636-3944)
- Maurizio Scaltriti (ORCID: https://orcid.org/0000-0002-5522-1447)
- Srushti Kittane (ORCID: https://orcid.org/0000-0001-8776-2195)
- Wouter R. Karthaus (ORCID: https://orcid.org/0000-0002-9234-9044)
- Hongkai Ji (ORCID: https://orcid.org/0000-0002-6480-0141)
- Jillian R Love (ORCID: https://orcid.org/0009-0002-7773-067X)
- Erik Ladewig
- Lluís Morey (ORCID: https://orcid.org/0000-0001-9851-4066)
- Laura Baldino (ORCID: https://orcid.org/0009-0003-5930-4842)
- W. Nathaniel Brennen (ORCID: https://orcid.org/0000-0001-9807-7433)
- W. Chen (ORCID: https://orcid.org/0009-0006-0050-7364)
- Milad Razavi-Mohseni (ORCID: https://orcid.org/0000-0002-6052-3159)
- Xinyu Guo (ORCID: https://orcid.org/0000-0001-7309-566X)
- Emiliano Cocco (ORCID: https://orcid.org/0000-0002-1397-2656)
- Taibo Li (ORCID: https://orcid.org/0000-0002-6624-9293)
- Peihua Zhao (ORCID: https://orcid.org/0009-0007-7272-3274)
- Ryan Blawski (ORCID: https://orcid.org/0000-0002-3719-8343)
- Alexis Battle (ORCID: https://orcid.org/0000-0002-5287-627X)
- M Beer (ORCID: https://orcid.org/0000-0001-9955-3809)
- Susan L. Dalrymple (ORCID: https://orcid.org/0000-0003-1330-1964)
- Candice Stoudmann (ORCID: https://orcid.org/0009-0004-3920-4518)
- Liliana Garcia-Martinez (ORCID: https://orcid.org/0000-0002-3015-5543)
- Mirna Sallaku (ORCID: https://orcid.org/0009-0009-2346-4434)
- Eneda Toska (ORCID: https://orcid.org/0000-0002-8974-9792)
- Pau Castel (ORCID: https://orcid.org/0000-0002-4972-4347)
- Christina S. Leslie (ORCID: https://orcid.org/0000-0002-4571-5910)
- Ingrid Kalemi (ORCID: https://orcid.org/0009-0009-0703-6624)
- Nachiket Kelkar (ORCID: https://orcid.org/0000-0003-2235-665X)
- F. Javier Carmona (ORCID: https://orcid.org/0000-0001-7904-8493)
- Huayang Liu (ORCID: https://orcid.org/0009-0006-7994-3408)
- Ho Man Chan (ORCID: https://orcid.org/0000-0002-1117-1230)
Institutions
- Ikerbasque (ES)
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- University of Miami (US)
- University of the Basque Country (ES)
- Johns Hopkins Medicine (US)
- Johns Hopkins University Applied Physics Laboratory (US)
- NYU Langone Health (US)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Formation Continue UNIL-EPFL (CH)
- Vall d'Hebron Institut de Recerca (ES)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- Ludwig Cancer Research (CH)
- University of Miami Hospital (US)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Japan) (JP)
- Johns Hopkins Hospital (US)
- Sylvester Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- École Polytechnique Fédérale de Lausanne (CH)
- New York University (US)
- KU Leuven (BE)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1158/0008-5472.can-25-2053
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00